Shigeru Suga1, Bin Chang2, Kazutoyo Asada3, Hideki Akeda4, Junichiro Nishi5, Kenji Okada6, Hiroshi Wakiguchi7, Akihiko Maeda8, Megumi Oda9, Naruhiko Ishiwada10, Akihiko Saitoh11, Tomohiro Oishi11, Mitsuaki Hosoya12, Takehiro Togashi13, Kazunori Oishi2, Toshiaki Ihara3. 1. Infectious Disease Center and Department of Clinical Research, National Hospital Organization Mie Hospital, Mie, Japan. Electronic address: sugas@mie-m.hosp.go.jp. 2. National Institute of Infectious Diseases, Tokyo, Japan. 3. Infectious Disease Center and Department of Clinical Research, National Hospital Organization Mie Hospital, Mie, Japan. 4. Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Okinawa, Japan. 5. Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. 6. Section of Pediatrics, Department of Medicine, Division of Oral and Medical Management, Fukuoka Dental College, Fukuoka, Japan. 7. Kochi University, Kochi, Japan. 8. Department of Pediatrics, Kochi Prefectural Hata-Kenmin Hospital, Kochi, Japan. 9. Okayama University Graduate School of Health Sciences, Okayama, Japan. 10. Department of Infectious Diseases, Medical Mycology Research Center, Chiba University, Chiba, Japan. 11. Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. 12. Department of Pediatrics, Fukushima Medical University School of Medicine, Fukushima, Japan. 13. Sapporo City University School of Nursing, Hokkaido, Japan.
Abstract
BACKGROUND: In Japan, the seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2010. PCV13 has replaced PCV7 since November 2013. METHODS: The effectiveness of PCV7 in protecting against invasive pneumococcal disease (IPD) in children aged <5 years was evaluated in a nationwide active population-based surveillance of IPD in 2008-2013 in 10 prefectures in Japan. RESULTS: 1181 cases were identified; 711 pneumococcal strains were analyzed for serotyping and antimicrobial resistance. Compared with the baseline IPD incidence (25.0 per 100,000), a 98% decline in IPD caused by PCV7 serotypes was found after the introduction of PCV7. This was partially offset by an increased incidence of IPD caused by PCV13 minus PCV7 and non-PCV13 serotypes, resulting in a 57% decline in overall IPD incidence. Absolute increases in the incidence rates of IPD caused by PCV13 minus PCV7 and non-PCV13 serotypes were 2.1 and 2.8 per 100,000 during the study period, respectively. The proportion of meropenem-nonsusceptible strains, especially with serotypes 19A and 15A, increased significantly after PCV7 introduction. CONCLUSIONS: Our data confirmed a 98% decline in IPD incidence caused by PCV7 serotypes in children aged <5 years and serotype replacement after PCV7 introduction. This shows the importance of continuing surveillance of serotypes responsible for IPD and their antimicrobial resistance in Japan.
BACKGROUND: In Japan, the seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2010. PCV13 has replaced PCV7 since November 2013. METHODS: The effectiveness of PCV7 in protecting against invasive pneumococcal disease (IPD) in children aged <5 years was evaluated in a nationwide active population-based surveillance of IPD in 2008-2013 in 10 prefectures in Japan. RESULTS: 1181 cases were identified; 711 pneumococcal strains were analyzed for serotyping and antimicrobial resistance. Compared with the baseline IPD incidence (25.0 per 100,000), a 98% decline in IPD caused by PCV7 serotypes was found after the introduction of PCV7. This was partially offset by an increased incidence of IPD caused by PCV13 minus PCV7 and non-PCV13 serotypes, resulting in a 57% decline in overall IPD incidence. Absolute increases in the incidence rates of IPD caused by PCV13 minus PCV7 and non-PCV13 serotypes were 2.1 and 2.8 per 100,000 during the study period, respectively. The proportion of meropenem-nonsusceptible strains, especially with serotypes 19A and 15A, increased significantly after PCV7 introduction. CONCLUSIONS: Our data confirmed a 98% decline in IPD incidence caused by PCV7 serotypes in children aged <5 years and serotype replacement after PCV7 introduction. This shows the importance of continuing surveillance of serotypes responsible for IPD and their antimicrobial resistance in Japan.
Authors: David Fitz-Patrick; Mariano Young; Daniel A Scott; Ingrid L Scully; Gary Baugher; Yahong Peng; Kathrin U Jansen; William Gruber; Wendy Watson Journal: Hum Vaccin Immunother Date: 2021-02-05 Impact factor: 3.452
Authors: Carmen Sheppard; Norman K Fry; Shazad Mushtaq; Neil Woodford; Rosy Reynolds; Regina Janes; Rachel Pike; Robert Hill; Maimuna Kimuli; Peter Staves; Michel Doumith; Timothy Harrison; David M Livermore Journal: Euro Surveill Date: 2016-12-15
Authors: T Ikuse; R Habuka; Y Wakamatsu; T Nakajima; N Saitoh; H Yoshida; B Chang; M Morita; M Ohnishi; K Oishi; A Saitoh Journal: Epidemiol Infect Date: 2018-08-02 Impact factor: 4.434